Shapiro S D, Fliszar C J, Broekelmann T J, Mecham R P, Senior R M, Welgus H G
Department of Medicine, Washington University School of Medicine, Jewish Hospital, St. Louis, Missouri 63110.
J Biol Chem. 1995 Mar 17;270(11):6351-6. doi: 10.1074/jbc.270.11.6351.
The matrix metalloproteinase 92-kDa gelatinase is a major product of inflammatory cells. Macrophages synthesize and secrete this proteinase as a proenzyme in association with tissue inhibitor of metalloproteinases (TIMP) (92TIMP), whereas neutrophils store and release it from secondary granules as a TIMP-free proenzyme (92TIMP-free). Metalloproteinase proenzymes can be activated in vitro by a variety of agents, including organomercurials and proteinases, resulting in loss of an 8-10-kDa NH2-terminal domain which disrupts the interaction of a conserved cysteine residue with the catalytic zinc molecule. We report that the activation and processing of 92-kDa gelatinase differs depending on its association with TIMP and the nature of the activating agent. We observed that 92TIMP undergoes classic activation to 82 kDa by stromelysin, whereas exposure to 4-aminophenylmercuric acetate (APMA) results in a final product of 83 kDa that still contains the "prodomain" cysteine. Association with TIMP appears to stabilize the COOH-terminal domain, whereas 92TIMP-free is converted by APMA to a final product of 67 kDa lacking the COOH-terminal portion. In the continued presence of APMA, which maintains cysteine-zinc disruption, the 67-kDa species is at least as active as the classic 82 kDa. In contrast, activation of 92TIMP-free by stromelysin initially generates the 82-kDa form which is followed by final conversion to a 50-kDa species that lacks the catalytic domain of the parent molecule. Therefore, although stromelysin activation of 92TIMP-free is initially efficient, the active 82-kDa form is short-lived and is replaced by an inactive 50-kDa product. This complex pattern of activation of the 92-kDa gelatinase may serve to restrict its proteolytic capacity following exposure to stromelysin and may serve to regulate proteinase activity in vivo.
基质金属蛋白酶92-kDa明胶酶是炎症细胞的主要产物。巨噬细胞将这种蛋白酶合成为与金属蛋白酶组织抑制剂(TIMP)结合的酶原(92TIMP)并分泌,而中性粒细胞将其作为无TIMP的酶原(无92TIMP)储存于次级颗粒中并从中释放。金属蛋白酶酶原在体外可被多种试剂激活,包括有机汞化合物和蛋白酶,导致一个8-10-kDa的NH2末端结构域丢失,这破坏了一个保守的半胱氨酸残基与催化锌分子的相互作用。我们报告92-kDa明胶酶的激活和加工因其与TIMP的结合情况以及激活剂的性质而有所不同。我们观察到92TIMP被基质溶素经典激活为82 kDa,而暴露于对氨基苯汞乙酸盐(APMA)会产生一个最终产物83 kDa,该产物仍含有“前结构域”半胱氨酸。与TIMP结合似乎能稳定COOH末端结构域,而无92TIMP被APMA转化为一个缺少COOH末端部分的67 kDa最终产物。在持续存在维持半胱氨酸-锌破坏的APMA的情况下,67-kDa的产物至少与经典的82 kDa一样有活性。相比之下,基质溶素对无92TIMP的激活最初产生82-kDa的形式,随后最终转化为一个缺少母体分子催化结构域的50-kDa产物。因此,尽管基质溶素对无92TIMP的激活最初是有效的,但活性82-kDa的形式是短暂的,并被无活性的50-kDa产物取代。92-kDa明胶酶这种复杂的激活模式可能有助于限制其在暴露于基质溶素后的蛋白水解能力,并可能有助于在体内调节蛋白酶活性。